Mega Genomics Limited (HKG:6667)

Market Cap	1.54B -35.3%
Revenue (ttm)	275.03M +50.5%
Net Income	30.07M -40.0%
EPS	0.15 -37.0%
Shares Out	224.30M
PE Ratio	44.98
Forward PE	n/a
Dividend	0.17 (2.52%)
Ex-Dividend Date	n/a

Volume	2,200
Average Volume	2,110
Open	6.80
Previous Close	6.80
Day's Range	6.78 - 6.81
52-Week Range	6.19 - 7.53
Beta	0.79
RSI	33.57
Earnings Date	May 29, 2026

About Mega Genomics

Mega Genomics Limited, a genetic testing platform company, offers consumer genetic testing and cancer screening services in China. It offers brain health assessment package, a service that assesses the risk of various related diseases, including Alzheimer’s disease; alimentation capability assessment package, a service that assesses the risk of developing hyperhomocysteinemia; Parkinson’s disease risk assessment; full-scale cancer risk assessment packages; myocardial infarction and heart failure genetic testing, a service and ancillary service ...

• Industry: Diagnostics & Research
• Sector: Healthcare
• Founded: 2016
• Employees: 206
• Stock Exchange: Hong Kong Stock Exchange
• Ticker Symbol: 6667

Financial Performance

In 2025, Mega Genomics's revenue was 247.15 million, an increase of 50.49% compared to the previous year's 164.23 million. Earnings were 27.02 million, a decrease of -40.01%.

Financial numbers in CNY